Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine։
”Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Patients with DVT or PE were randomly assigned in a 1:1 ratio to rivaroxaban 15 mg twice daily for 21 days, apixaban 20 mg/day or apixaban 10 mg twice daily for 7 days, followed by apixaban 5 mg twice daily, both groups for 3 months.
The primary outcome (PO) was clinically relevant bleeding (CRB), a composite of clinically relevant non-major bleeding (CRNMB) or clinically relevant non-major bleeding according to the ISTH, and major bleeding (MB). The secondary outcomes (SO) were the individual components of the primary PE: recurrent DVT/PE.
CRB was observed in 3.3% with Apixaban versus 7.1% with Rivaroxaban (Relative Risk: 0.46; 95% CI, 0.33 to 0.65; P<0.001). MB 0.4% versus 2.4%; Relative Risk: 0.16; 95% CI, 0.06 to 0.40.
The percentage of DVT/PE recurrence was similar in the two treatment groups at 3 months
These data cannot be extrapolated to atrial fibrillation; the COBBRA-AF study on atrial fibrillation is currently underway.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 14:58Heghine Khachatryan: PFO, Cryptogenic Stroke, and Factor V Leiden – Closure or Lifelong Anticoagulation?
-
Mar 17, 2026, 14:56Mahesan Subramaniam: A Visual Guide to Heart Valve Disease
-
Mar 17, 2026, 14:52Kanishk Kumar: ATTR Amyloidosis Therapeutics Market Poised for a Pipeline Revolution
-
Mar 17, 2026, 14:39Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
-
Mar 17, 2026, 14:34Rishi Wadhera: Financial Burden Among Working-Age Adults With Cardiovascular Disease
-
Mar 17, 2026, 14:32Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
-
Mar 17, 2026, 14:31Applications Now Open for ISTH Fundamental Research Career Award
-
Mar 17, 2026, 14:29Balancing Bleeding and Clotting in Decompensated Cirrhosis – JTH
-
Mar 17, 2026, 14:07Gayatri Digambar: Silent Plaque Rupture – The Hidden Trigger Behind Acute MI